<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642457</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 17-1294</org_study_id>
    <nct_id>NCT03642457</nct_id>
  </id_info>
  <brief_title>Efficacy Between Serratus Plane Block And Local Infiltration In Vats</brief_title>
  <official_title>Comparison Between Serratus Plane Block And Local Surgical Infiltration In Robotic Video Assisted Thoracoscopic Surgery- A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Robotic video-assisted thoracoscopic surgery (VATS) is increasingly being used as it is a&#xD;
      less invasive surgery compared to traditional methods, but the acute pain at an early stage&#xD;
      after VATS has a major impact on perioperative outcomes. Effective post operative analgesia&#xD;
      is believed to reduce morbidity, quicken recovery, improve patient outcome and reduce&#xD;
      hospital costs. The site and extent of the incision influences the degree of pain due to&#xD;
      disruption of intercostal nerves as well as inflammation of chest wall and pleura. Neuraxial&#xD;
      and systemic opioids have been a gold standard as a part of multimodal analgesia for thoracic&#xD;
      surgeries. Numerous modalities have been studied: thoracic paravertebral nerve blocks,&#xD;
      thoracic epidural analgesia, intercostal nerve blocks, patient controlled analgesia (PCA),&#xD;
      cryo-analgesia, transcutaneous electrical nerve stimulation (TENS), inter-pleural blocks,&#xD;
      stellate ganglion blocks, long thoracic nerve blocks, and infiltration under direct vision by&#xD;
      the surgeon.&#xD;
&#xD;
      Serratus plane block is an emerging regional technique that has proven to be effective in&#xD;
      comparison to paravertebral blocks in patients undergoing breast surgery and mastectomy with&#xD;
      reduced perioperative opioid consumption and improved pain scores.&#xD;
&#xD;
      The lateral pectoral nerve, medial pectoral nerve, intercostal nerves and long thoracic nerve&#xD;
      are all targets for the serratus plane block. It can be safely performed under ultrasound&#xD;
      guidance.&#xD;
&#xD;
      The purpose of the study is to evaluate the difference in quality of analgesia between&#xD;
      efficacy of serratus plane block and local surgical infiltration by surgeon as measured by&#xD;
      patient opioid consumption and pain scores.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be assigned randomly using a computer-generated table of numbers to either&#xD;
      serratus group or infiltration group. Block team will perform all blocks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left institution and unable to find new PI&#xD;
  </why_stopped>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The patient, surgeon, and anesthesiologist in the case will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of Opioid Consumption</measure>
    <time_frame>up to 24 hours post procedure</time_frame>
    <description>The amount of opioid consumption (in mg IV morphine equivalents) postoperatively up to 24 hours after the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Dose of Narcotic Administration</measure>
    <time_frame>up to 24 hours post procedure</time_frame>
    <description>Time to first dose of narcotic administration post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACU Length of Stay</measure>
    <time_frame>average 3-4 hours post procedure</time_frame>
    <description>The length of stay post procedure in the PACU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>up to 40 hours post procedure</time_frame>
    <description>The length of stay post procedure in the or ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Score (VAS)</measure>
    <time_frame>up to 24 hours post procedure</time_frame>
    <description>Visual Analogue Score (VAS) pain score from 0 (no pain) to 10 (most pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction Score</measure>
    <time_frame>up to 24 hours post procedure</time_frame>
    <description>Patient satisfaction score from 0 (not satisfied) to 10 (extremely satisfied)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Serratus Plane Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>20 cc 0.5%</description>
    <arm_group_label>Serratus Plane Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine liposome</intervention_name>
    <description>133mg liposomal bupivacaine</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_label>Serratus Plane Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA (American Society of Anesthesiology) class I-IV&#xD;
&#xD;
          -  age 81-75&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA class V&#xD;
&#xD;
          -  morbid obesity&#xD;
&#xD;
          -  patient refusal&#xD;
&#xD;
          -  patients with chronic pain or on pain medications&#xD;
&#xD;
          -  allergy to LA&#xD;
&#xD;
          -  patients receiving any additional regional techniques&#xD;
&#xD;
          -  coagulopathy&#xD;
&#xD;
          -  patients receiving systemic anticoagulation&#xD;
&#xD;
          -  local infection&#xD;
&#xD;
          -  procedures anticipated to last more than 5 hours.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Lai, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>cahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai St. Luke's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai West Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kulhari S, Bharti N, Bala I, Arora S, Singh G. Efficacy of pectoral nerve block versus thoracic paravertebral block for postoperative analgesia after radical mastectomy: a randomized controlled trial. Br J Anaesth. 2016 Sep;117(3):382-6. doi: 10.1093/bja/aew223.</citation>
    <PMID>27543533</PMID>
  </reference>
  <reference>
    <citation>Blanco R. The 'pecs block': a novel technique for providing analgesia after breast surgery. Anaesthesia. 2011 Sep;66(9):847-8. doi: 10.1111/j.1365-2044.2011.06838.x.</citation>
    <PMID>21831090</PMID>
  </reference>
  <reference>
    <citation>Thoracic paravertebral block versus pectoral nerve block for analgesia after breast surgery. Egypt J Anaesth. 2013; 30: 129-135. Wahba, SS and Kamal, SM.</citation>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <results_first_submitted>August 3, 2020</results_first_submitted>
  <results_first_submitted_qc>August 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2020</results_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Yan Lai</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Video assisted thoracoscopic surgery</keyword>
  <keyword>Serratus plane block</keyword>
  <keyword>local infiltration</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03642457/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Serratus Plane Group</title>
          <description>Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Serratus Plane Group</title>
          <description>Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.29" spread="17.24"/>
                    <measurement group_id="B2" value="64.30" spread="11.01"/>
                    <measurement group_id="B3" value="58.37" spread="15.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>missing data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Amount of Opioid Consumption</title>
        <description>The amount of opioid consumption (in mg IV morphine equivalents) postoperatively up to 24 hours after the procedure.</description>
        <time_frame>up to 24 hours post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Serratus Plane Group</title>
            <description>Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Opioid Consumption</title>
          <description>The amount of opioid consumption (in mg IV morphine equivalents) postoperatively up to 24 hours after the procedure.</description>
          <units>MME</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.93" spread="19.16"/>
                    <measurement group_id="O2" value="13.21" spread="18.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Dose of Narcotic Administration</title>
        <description>Time to first dose of narcotic administration post procedure</description>
        <time_frame>up to 24 hours post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Serratus Plane Group</title>
            <description>Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Dose of Narcotic Administration</title>
          <description>Time to first dose of narcotic administration post procedure</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread="4.17"/>
                    <measurement group_id="O2" value="3.09" spread="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PACU Length of Stay</title>
        <description>The length of stay post procedure in the PACU</description>
        <time_frame>average 3-4 hours post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Serratus Plane Group</title>
            <description>Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>PACU Length of Stay</title>
          <description>The length of stay post procedure in the PACU</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="2.41"/>
                    <measurement group_id="O2" value="3.05" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Length of Stay</title>
        <description>The length of stay post procedure in the or ICU</description>
        <time_frame>up to 40 hours post procedure</time_frame>
        <population>only those participants who required an ICU stay</population>
        <group_list>
          <group group_id="O1">
            <title>Serratus Plane Group</title>
            <description>Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Length of Stay</title>
          <description>The length of stay post procedure in the or ICU</description>
          <population>only those participants who required an ICU stay</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.57" spread="28.32"/>
                    <measurement group_id="O2" value="40.00" spread="27.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analogue Score (VAS)</title>
        <description>Visual Analogue Score (VAS) pain score from 0 (no pain) to 10 (most pain)</description>
        <time_frame>up to 24 hours post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Serratus Plane Group</title>
            <description>Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Score (VAS)</title>
          <description>Visual Analogue Score (VAS) pain score from 0 (no pain) to 10 (most pain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="3.56"/>
                    <measurement group_id="O2" value="2.80" spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" spread="2.85"/>
                    <measurement group_id="O2" value="3.07" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="2.71"/>
                    <measurement group_id="O2" value="3.23" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 18 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="2.94"/>
                    <measurement group_id="O2" value="2.17" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="2.26"/>
                    <measurement group_id="O2" value="1.93" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction Score</title>
        <description>Patient satisfaction score from 0 (not satisfied) to 10 (extremely satisfied)</description>
        <time_frame>up to 24 hours post procedure</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Serratus Plane Group</title>
            <description>Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction Score</title>
          <description>Patient satisfaction score from 0 (not satisfied) to 10 (extremely satisfied)</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Serratus Plane Group</title>
          <description>Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Poonam Pai</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>347-569-4816</phone>
      <email>poonam.paibantwalhebbalasankatte@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

